Literature DB >> 6547636

Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.

D W Fry, J A Besserer, T J Boritzki.   

Abstract

Cl-920 is a structurally novel antitumor antibiotic which has activity against a wide spectrum of tumor cells in vitro and is curative in L1210 leukemia in vivo. Several lines of evidence indicate that this drug penetrates L1210 cells via the reduced folate carrier system. Reduced folates (100 microM) including leucovorin and 5-methyltetrahydrofolate completely protected L1210 cells from growth inhibition by Cl-920. Protective effects were not observed, however, with folic acid, a compound which is transported by a process distinct from that for reduced folates. Cl-920 was a potent inhibitor of methotrexate influx exhibiting a mixture of competitive and noncompetitive inhibition and having a Ki (slope) of 30.0 microM and a Ki (intercept) of 58.8 microM. The inhibition appeared to be irreversible since, after cells were preincubated with drug, the inhibitory effects persisted after cells were washed in drug-free media. The irreversibility could be eliminated, however, by dithiothreitol, suggesting that Cl-920 may interact with a thiol which is essential to this transport system. Cells made 71-fold resistant to Cl-920 by continuous exposure to increasing concentrations of this drug were 245-fold cross-resistant to methotrexate but were collaterally sensitive to the lipophilic antifolate trimetrexate and contained normal levels of dihydrofolate reductase. This mutant cell line had a severely impaired reduced folate carrier system exhibiting methotrexate influx rates of less than 1% of control cells. Finally, inhibition of methotrexate influx by a number of Cl-920 analogues showed that the intact lactone ring and the presence of the phosphate ester were required for maximum interaction with the carrier system and that the degree of inhibition correlated with relative antitumor potency. These observations are compatible with the concept that Cl-920 utilizes the folate carrier system and could be of fundamental importance for understanding the cytotoxicity and selectivity of Cl-920.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547636

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse.

Authors:  Mark Swingle; Li Ni; Richard E Honkanen
Journal:  Methods Mol Biol       Date:  2007

2.  Cellular transport of CI-980.

Authors:  K E Hook; S A Przybranowski; W R Leopold
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721).

Authors:  B J Roberts; K L Hamelehle; J S Sebolt; W R Leopold
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Application of a new preclinical drug screening system for cancer of the large bowel.

Authors:  W Scheithauer; M P Moyer; G M Clark; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells.

Authors:  C M Gedik; A R Collins
Journal:  Nucleic Acids Res       Date:  1990-02-25       Impact factor: 16.971

6.  AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase.

Authors:  T J Boritzki; C A Barlett; C Zhang; E F Howland
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

7.  Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Authors:  Benjamin Theobald; Kathy Bonness; Alla Musiyenko; Joel F Andrews; Gudrun Urban; Xizhong Huang; Nicholas M Dean; Richard E Honkanen
Journal:  Mol Cancer Res       Date:  2013-05-13       Impact factor: 5.852

8.  Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.

Authors:  S de Jong; J G Zijlstra; N H Mulder; E G de Vries
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

10.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

Authors:  A L Jackman; L R Kelland; R Kimbell; M Brown; W Gibson; G W Aherne; A Hardcastle; F T Boyle
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.